Panobinostat

Drug Profile

Panobinostat

Alternative Names: Farydak; LBH-589; LBH-589A

Latest Information Update: 25 Jul 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Georgia Regents University; H. Lee Moffitt Cancer Center and Research Institute; HOVON Foundation; Mayo Clinic; National Cancer Institute (USA); New York University School of Medicine; Novartis; Peter MacCallum Cancer Centre; St. Jude Childrens Research Hospital; Therapeutic Advances in Childhood Leukemia & Lymphoma; Thomas Jefferson University; University of Aarhus; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II/III Chronic myeloid leukaemia
  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Myelofibrosis; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Renal cell carcinoma; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Breast cancer; HIV-1 infections; Hodgkin's disease; Malignant melanoma
  • Phase I Brain metastases; CNS cancer; Gastrointestinal stromal tumours; Head and neck cancer; Mantle-cell lymphoma; Non-small cell lung cancer; Solid tumours
  • Preclinical Small cell lung cancer
  • No development reported Glioma; Pancreatic cancer
  • Discontinued Cutaneous T cell lymphoma; Prostate cancer

Most Recent Events

  • 14 Jul 2017 Novartis plans the phase I/II HOVON 148 AML trial for Acute myeloid leukaemia (In adults, In the elderly, Combination therapy, Prevention) in the Netherlands (NTR6511)
  • 05 Jul 2017 Novartis terminates a phase I/II trial in Malignant melanoma (Combination therapy, Metastatic disease) in USA due to change in the number of approved drugs for metastatic melanoma (PO) (NCT00925132)
  • 19 Jun 2017 Novartis terminates a phase II trial in Neuroendocrine tumours (Metastatic disease, Second-line therapy or greater) in USA as study did not meet statistical requirements to continue (NCT00985946)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top